1. Home
  2. SNY vs NEA Comparison

SNY vs NEA Comparison

Compare SNY & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • NEA
  • Stock Information
  • Founded
  • SNY 1994
  • NEA 2002
  • Country
  • SNY France
  • NEA United States
  • Employees
  • SNY N/A
  • NEA N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • NEA Finance/Investors Services
  • Sector
  • SNY Health Care
  • NEA Finance
  • Exchange
  • SNY Nasdaq
  • NEA Nasdaq
  • Market Cap
  • SNY 116.5B
  • NEA 3.3B
  • IPO Year
  • SNY N/A
  • NEA N/A
  • Fundamental
  • Price
  • SNY $48.61
  • NEA $10.94
  • Analyst Decision
  • SNY Buy
  • NEA
  • Analyst Count
  • SNY 2
  • NEA 0
  • Target Price
  • SNY $62.50
  • NEA N/A
  • AVG Volume (30 Days)
  • SNY 2.2M
  • NEA 803.4K
  • Earning Date
  • SNY 07-31-2025
  • NEA 01-01-0001
  • Dividend Yield
  • SNY 3.29%
  • NEA 4.23%
  • EPS Growth
  • SNY 39.56
  • NEA N/A
  • EPS
  • SNY 5.45
  • NEA N/A
  • Revenue
  • SNY $48,817,552,946.00
  • NEA N/A
  • Revenue This Year
  • SNY $3.39
  • NEA N/A
  • Revenue Next Year
  • SNY $7.05
  • NEA N/A
  • P/E Ratio
  • SNY $17.37
  • NEA N/A
  • Revenue Growth
  • SNY N/A
  • NEA N/A
  • 52 Week Low
  • SNY $45.80
  • NEA $9.20
  • 52 Week High
  • SNY $60.12
  • NEA $11.37
  • Technical
  • Relative Strength Index (RSI)
  • SNY 46.26
  • NEA 53.97
  • Support Level
  • SNY $47.99
  • NEA $10.79
  • Resistance Level
  • SNY $49.43
  • NEA $11.04
  • Average True Range (ATR)
  • SNY 0.58
  • NEA 0.05
  • MACD
  • SNY 0.18
  • NEA 0.01
  • Stochastic Oscillator
  • SNY 56.15
  • NEA 64.29

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01

Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.

Share on Social Networks: